Meningococcal polysaccharide vaccine group W-135

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Meningococcal polysaccharide vaccine group W-135
Accession Number
DB13887  (DB10074)
Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Description

Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

Synonyms
  • Meningococcal polysaccharide antigen group W-135
  • neisseria meningitidis group W-135 capsular polysaccharide antigen
  • Neisseria meningitidis group W-135 polysaccharide antigen, A
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)KitSanofi Pasteur Limited1981-11-23Not applicableUs
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (50 mcg) + Meningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Meningococcal polysaccharide vaccine group Y (50 mcg)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (2.5 mg) + Meningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Meningococcal polysaccharide vaccine group Y (2.5 mg)Powder, for solutionSubcutaneousAventis Pasteur Limited1998-08-132006-07-17Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (500 mcg) + Meningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Meningococcal polysaccharide vaccine group Y (500 mcg)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada
MenveoMeningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada
NimenrixMeningococcal polysaccharide vaccine group W-135 (5 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (44 mcg) + Meningococcal polysaccharide vaccine group A (5 mcg) + Meningococcal polysaccharide vaccine group C (5 mcg) + Meningococcal polysaccharide vaccine group Y (5 mcg)Kit; Powder, for solutionIntramuscularPfizer2013-08-22Not applicableCanada
Categories
UNII
9F8QQ6EER1
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911456
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingPreventionInfections, Respiratory Syncytial Virus1
1, 2Active Not RecruitingPreventionRespiratory Syncytial Virus (RSV)1
2CompletedPreventionHealthy Volunteers / Meningococcal Infections1
2CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1
2CompletedPreventionMeningococcal Disease / Meningococcal Infections1
2CompletedPreventionMeningococcal Infections1
2RecruitingPreventionMeningococcal Meningitis1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3CompletedPreventionMeningitis / Meningococcal Meningitis1
3CompletedPreventionMeningococcal Disease / Meningococcal Infections1
3CompletedPreventionMeningococcal Infections4
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases1
3Not Yet RecruitingPreventionMeningococcal Infection (Healthy Volunteers)1
3RecruitingPreventionMeningococcal Infections2
4RecruitingOtherMeningococcal Meningitis1
4RecruitingPreventionMeningococcal Disease, Invasive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
Kit; powder, for solutionSubcutaneous
Powder, for solutionSubcutaneous
Powder, for solution; solutionIntramuscular
Kit; powder, for solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on September 08, 2017 14:22 / Updated on May 01, 2019 11:53